CA-COVID
Coagulopathy Associated with COVID-19 (CA-COVID19): A multi-centre observational study in the UK
CA-COVID19 is a retrospective-prospective multi-centre observational study that aims to document the coagulation abnormalities present in patients presenting with COVID19 infection.
The primary objective is to assess the predictive value of coagulopathic changes for the development of respiratory failure, multiorgan failure and death.
Contact: p.nicolson@bham.ac.uk
Read More
This NIHR-supported study has been developed by Imperial College London, in conjunction with HaemSTAR, and is being launched across the UK in June 2020. Please speak to your local HaemSTAR representative to find out more about registering your own clinical site with CA-COVID19.
As of October 2020, data on over 5700 patients has been submitted and the study remains open to new recruitment.
Useful Documents
Lay Summary
COVID-19 can affect the blood’s ability to clot, which may contribute to serious complications such as breathing failure, organ problems, or death. The CA-COVID19 audit looked at patients with COVID-19 across multiple UK hospitals to understand these blood clotting changes and how they relate to illness severity. The findings help doctors identify patients at higher risk and improve treatment and outcomes for people with COVID-19.